BioSpace News Archive

Business

Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights

Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, reported its third quarter 2019 financial results, program progress and corporate updates.

November 6, 2019
·
9 min read
Business

Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program

Achieve Life Sciences, Inc. provided an update on the cytisinicline clinical development program and announced third quarter 2019 financial results.

November 6, 2019
·
7 min read
Business

Amneal Enters into a Licensing Agreement with Kashiv BioSciences, LLC to Develop and Commercialize K127 for the Treatment of Myasthenia Gravis

Expands Amneal’s Central Nervous System (CNS) Focused Development Pipeline with Orphan Drug

November 6, 2019
·
5 min read
Business

CVS Health Reports Third Quarter Results

2019 EPS Guidance Raised And Narrowed, Reflecting Strong Execution Of Strategic Long-Term Plan

November 6, 2019
·
51 min read
15 Years of P-MEC China Driving Global Pharma Technology Forward in China

P-MEC China, co-organized by Informa Markets, CCCMHPIE and Sinoexpo Informa Markets, will take place at the Shanghai New International Expo Center from June 22-24, 2020.

November 6, 2019
·
3 min read
Business

Vifor Pharma and Evotec form joint venture for early development in nephrology

Vifor Pharma and Evotec to create a jointly-owned drug discovery and development platform for innovative nephrology therapeutics

November 6, 2019
·
5 min read
Nanoform Wins the CPhI Excellence in Pharma Award for Formulation

Nanoform, an innovative medicine enabling nanotechnology company, has won the Excellence in Pharma Award for Formulation at the prestigious CPhI Pharma Awards.

November 6, 2019
·
2 min read
Business

Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

Positive Topline Results from BELIEVE 1 Phase 2 Trial of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies Suggest Compelling Seizure Reductions and Excellent Tolerability

November 6, 2019
·
15 min read
Drug Development

Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials

Data from the Two 144-week Studies in Treatment-naïve Adults Living with HIV Presented at European AIDS Conference (EACS)

November 6, 2019
·
10 min read